Related Experiment Video
Updated: Mar 28, 2026
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
Expression of Cell Surface Receptors on Human Glioblastoma Xenograft Model in NOD/SCID Mouse
Purpose:
To obtain basic data for development of a glioblastoma-specific immunotoxin, the expression of variable cell surface receptors on a human glioblastoma xenograft model was evaluated, using NOD/SCID mice.
Materials And Methods:
We developed a xenograft model in NOD/SCID mice implanted with a human glioblastoma cell line (U-87MG). Immunohistochemical studies were performed on implanted tumor nodules (n=8) using antibodies against CD71, EGFR, IGF-IRalpha, CXCR4 and IL-4Ralpha.
Results:
Expression of IL-4Ralpha, in implanted tumornodules, was the highest of the cell surface receptors evaluated in this study. However, the endothelial cells in, and around, the tumor nodules also revealed immunopositivity against IL-4Ralpha. The immunoreactivity of IL-4Ralpha, and other surface receptors such as CD71, IGF-IRalpha and EGFR, was prominent in tumor nodules associated with tumor necrosis.
Conclusion:
IL-4Ralpha would be a possible target for the development of glioblastoma-specific immunotoxin, although there are limitations due to its endothelial expression.
Insights
Interleukin-4 receptor alpha (IL-4Ralpha) shows high expression in glioblastoma xenografts, making it a potential target for immunotoxin development. However, its presence on endothelial cells presents challenges.
Area of Science:
- Neuro-oncology
- Immunotherapy
- Molecular Biology
Background:
- Glioblastoma is an aggressive brain tumor with limited treatment options.
- Targeted therapies, such as immunotoxins, offer potential for glioblastoma treatment.
- Identifying specific cell surface receptors is crucial for developing targeted therapies.
Purpose of the Study:
- To evaluate the expression of cell surface receptors on a human glioblastoma xenograft model.
- To identify potential targets for glioblastoma-specific immunotoxin development.
Main Methods:
- A human glioblastoma xenograft model (U-87MG) was established in NOD/SCID mice.
- Immunohistochemical studies were performed on tumor nodules using antibodies against CD71, EGFR, IGF-IRalpha, CXCR4, and IL-4Ralpha.
Main Results:
- Interleukin-4 receptor alpha (IL-4Ralpha) exhibited the highest expression among the evaluated cell surface receptors.
- IL-4Ralpha expression was also detected on endothelial cells within and surrounding the tumor nodules.
- Receptor expression, including IL-4Ralpha, CD71, IGF-IRalpha, and EGFR, was prominent in tumor nodules associated with necrosis.
Conclusions:
- IL-4Ralpha is a potential target for glioblastoma-specific immunotoxin development.
- Endothelial expression of IL-4Ralpha poses a limitation that needs to be addressed for targeted therapy development.
